Form 4: IRIDEX Director Scott Shuda Granted 53,000 Stock Options

IRIDEX Corp. Director Scott Shuda was granted 53,000 derivative securities, specifically stock options, with vesting commencing on June 13, 2025.

Summary

• Scott Shuda, a Director of IRIDEX Corp. (IRIX), was granted 53,000 derivative securities in the form of stock options.
• The transaction date for this grant was June 13, 2025.
• The exercise price for these options is $1.4 per share.
• The derivative securities themselves were acquired at a price of $0, indicating they were granted as compensation.
• The options are exercisable starting June 13, 2025, and have an expiration date of June 13, 2032.
• The vesting schedule for these shares is detailed as: 1/3 of the shares subject to the option will vest each one-year anniversary of the grant date.
• Additionally, 100% of the shares will vest each one-year anniversary of the grant date or the Company's 2026 Annual Meeting of Stockholders.
• Following this transaction, Scott Shuda beneficially owns 53,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns the director's financial interests with the long-term performance of the company, indicating continued commitment and incentivizing value creation for shareholders.

Positives

• The grant of stock options to Director Scott Shuda aligns his interests with those of shareholders, incentivizing long-term company performance.
• This is a standard practice for director compensation, indicating continued commitment from the board member.

Negatives

• The grant of options, if exercised in the future, could lead to a slight dilution of existing shares, although this is typical for equity compensation plans.
• This transaction does not represent a direct cash investment by the director into the company's stock.

Risks

• Potential future dilution of existing shares if the granted options are exercised.
• The value of the options is dependent on the future market price of IRIDEX Corp. common stock, which is subject to market fluctuations.

Future Outlook

The future outlook related to this grant involves the vesting of the options over time, with the first tranche becoming exercisable on June 13, 2025, and subsequent vesting occurring annually or potentially accelerated by the Company's 2026 Annual Meeting of Stockholders. The director may choose to exercise these options at any point before their expiration in 2032, subject to vesting conditions and market conditions.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation. It does not provide broader industry trends or competitive analysis, but it reflects a common practice within the medical device or healthcare technology sector where equity grants are used to incentivize and retain key personnel.

Related Party Transactions

• The grant of stock options to Scott Shuda, a Director of IRIDEX Corp., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned interests between the director and company performance.
• Director (Scott Shuda): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• Continued vesting of the 53,000 stock options according to the specified schedules (1/3 annually or 100% by 2026 Annual Meeting).
• Potential exercise of the vested options by Scott Shuda prior to the June 13, 2032 expiration date.

Key Dates

Keywords

IRIDEX Corp, IRIX, Scott Shuda, SEC Form 4, Stock Options, Derivative Securities, Insider Transaction, Director Compensation, Equity Grant, Vesting Schedule